Nalagenetics announced Friday the closing of a $12.6 million Series A round of financing co-led by Intudo Ventures and Vulcan Capital. The round also saw participation from strategic investors, including Singapore-based Diagnostics Development Hub (DxD Hub) through the Agency for Science, Technology and Research’s (A*STAR) A*ccelerate Technologies Pte Ltd, and Indonesia-based Dexa International, Diagnos Laboratories among others. With this round of financing, Nalagenetics plans to focus on product development for Clinical Decision Support (CDS) to enable whole genome analysis and integration with more providers and hospitals, and increase headcount with an emphasis on bioinformatics, software engineering, and genetics experts.